Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment

BACKGROUND: Cancer patients are at a higher risk of developing severe coronavirus disease 2019 (COVID-19). However, the safety and efficacy of COVID-19 vaccination in cancer patients undergoing treatment remain unclear. PATIENTS AND METHODS: In this interventional prospective multicohort study, prim...

Descripción completa

Detalles Bibliográficos
Autores principales: Peeters, M., Verbruggen, L., Teuwen, L., Vanhoutte, G., Vande Kerckhove, S., Peeters, B., Raats, S., Van der Massen, I., De Keersmaecker, S., Debie, Y., Huizing, M., Pannus, P., Neven, K., Ariën, K.K., Martens, G.A., Van Den Bulcke, M., Roelant, E., Desombere, I., Anguille, S., Goossens, M., Vandamme, T., van Dam, P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8423808/
https://www.ncbi.nlm.nih.gov/pubmed/34597941
http://dx.doi.org/10.1016/j.esmoop.2021.100274

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8423808/
https://www.ncbi.nlm.nih.gov/pubmed/34597941
http://dx.doi.org/10.1016/j.esmoop.2021.100274

Ejemplares similares